High Throughput Cancer Tissue Analysis for Personalised Therapy
Leaders. Professor Anna deFazio, Professor Rosemary Balleine, Professor Graham Mann
This Flagship Program aims to accelerate application of molecular analysis to clinical practice. It complements our considerable strengths in genomics with high-throughput proteomics using novel SWATH-MS (Sequential Window Acquisition of all Theoretical Mass Spectra) technology. This flagship contributes to the ProCan (Proteome of Human Cancer) initiative on the Westmead campus.
Lucas N, Robinson A, Espersen M, et al. Accelerated Barocycler Lysis and Extraction Sample Preparation for Clinical Proteomics by Mass Spectrometry Journal of Proteome Research 2019 18 (1), 399-405 doi: 10.1021/acs.jproteome.8b00684
Partner Program. Development of imaging biomarkers for personalised cancer therapies
Leaders. Professor Annette Haworth & A/Professor Verity Ahern
This project brings together an established medical physics team from the University of Sydney with clinical and research partners across the Sydney West Cancer Network. The program is dedicated to building non-invasive imaging biomarkers for the purpose of diagnosis, prognosis, treatment planning (chemotherapy, radiotherapy +/- immunotherapy) and treatment response with a particular interest in defining in vivo tumour heterogeneity for the purpose of personalised therapy.
Translational Program Grant
INOVATe – Individualised Ovarian Cancer Treatment Through Integration of Genomic Pathology into Multidisciplinary Care
Leader. Professor Anna deFazio
In this program a team of leading scientists and clinicians will develop strategies to treat patients according to ovarian cancer subtype, using new protocols for molecular testing and targeted therapeutic drugs. This will lead to personalised treatment which could improve survival of the 1,300 women in Australia and 200,000 women globally diagnosed with ovarian cancer each year.
Cancer Council NSW has awarded its annual $3.75M Translational Program Grant to the INOVATe research team, led by Professor Anna deFazio, exploring how to better personalise ovarian cancer treatment for Australian women. INOVATe 2.0 will run for the next 5 years. The team will analyse the molecular profile of over 300 ovarian cancer patients in NSW to better understand the subsets of ovarian cancer and how each type responds to specific treatments. The team will also look at ways of more simply communicating complex molecular test results to the treating clinical team, so they are easier to interpret. Finally, Professor deFazio’s team will use patient samples to print 3D models of ovarian tumours to test treatment approaches and help design new early phase clinical trials.